Armistice Capital’s Edwards Lifesciences EW Stock Holding History

Armistice Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18M	Sell	224,835 -52,643	-19%	-$4.34M	0.32%	63
2025 Q4	$23.7M	Buy	277,478 +130,907	+89%	+$10.7M	0.28%	58
2025 Q3	$11.4M	Buy	+146,571	New	+$11.5M	0.17%	80
2025 Q2	–	Sell	-62,995	Closed	-$4.57M	–	225
2025 Q1	$4.57M	Sell	62,995 -106,834	-63%	-$7.65M	0.07%	119
2024 Q4	$12.6M	Buy	169,829 +4,834	+3%	+$338K	0.17%	86
2024 Q3	$10.9M	Buy	+164,995	New	+$12M	0.17%	89

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Armistice Capital's EW Position: Q1 2026 in Review

Armistice Capital reduced its Edwards Lifesciences (EW) stake by 19% in Q1 2026, selling an estimated $4.34M and leaving 224,835 shares worth $18M. The position accounts for 0.32% of the portfolio, ranked #63.

Armistice Capital first reported a position in EW in Q3 2024 and has held it in 6 quarters since. The position peaked at $23.7M in Q4 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Armistice Capital held 224,835 shares of Edwards Lifesciences worth $18M as of Q1 2026.
Armistice Capital sold 52,643 Edwards Lifesciences shares in Q1 2026, an estimated $4.34M.
Edwards Lifesciences made up 0.32% of Armistice Capital's portfolio in Q1 2026, its #63 holding.
Armistice Capital first reported a position in Edwards Lifesciences in Q3 2024 and has held it in 6 quarters since.
Armistice Capital's Edwards Lifesciences position peaked at $23.7M in Q4 2025.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.